Kornimate/medical-research-clean huggingface dataset:
prostate magnetic resonance imaging in patient with previous negative biopsies

Conditions: Prostate Cancer

Summary: prostate cancer has been the most common neoplastic disease in men in finland over the last ten years. prostate-specific antigen (psa) plays an important role in screening of prostate cancer. however, psa has a limited sensitivity and specificity for prostate cancer detection. commonly, the diagnosis of prostate cancer is done by transrectal ultrasonography (trus) guided biopsy. because of the low accuracy of trus a systematic biopsy is usually performed instead of targeted trus biopsy. while, as many as 47% of the ultra-sound guided biopsies may be false negative and biopsies carry a risk of increase in complications, there is an increasing interest in developing more accurate non-invasive imaging modalities. this study will enroll 150 men with previous negative biopsies and clinical suspicion of prostate cancer due to serum level of psa higher than 2.5 ng/ml or abnormal digital rectal examination (dre) or patients in active surveillance due to low risk prostate carcinoma. anatomical magnetic resonance imaging (mri) and diffusion weighted imaging (dwi) at 3 tesla (t) magnetic field using surface coils will be used to non-invasively predict the presence or absence of prostate cancer. in addition to routine 12-core trus biopsies, targeted trus guided biopsy based on mri findings will be performed.


Eligibility criteria:
inclusion criteria: * language spoken: finnish or swedish * clinical suspicion of prostate cancer and/or previous negative prostate biopsies and mri target * previous diagnosis of prostate carcinoma and patient on active surveillance * mental status: patients must be able to understand the meaning of the study * informed consent: the patient must sign the appropriate ethics committee (ec) approved informed consent documents in the presence of the designated staff exclusion criteria: * language spoken: finnish or swedish * clinical suspicion of prostate cancer and/or previous negative prostate biopsies and mri target * previous diagnosis of prostate carcinoma and patient on active surveillance * mental status: patients must be able to understand the meaning of the study * informed consent: the patient must sign the appropriate ethics committee (ec) approved informed consent documents in the presence of the designated staff
fecal microbiota transplant in the treatment of ulcerative colitis

Conditions: Ulcerative Colitis, Active Moderate

Summary: the purpose of this study is to evaluate the effectiveness of fecal microbiota transplant (fmt) for treating patients with mild to moderate ulcerative colitis (uc). even with the expanding choices of medication for uc, physicians and patients are still in search of highly effective and safe medications with minimal side effects. fmt has been approved for the treatment of a bacterial infection called clostridium difficile. in this setting, fmt has been proven to be an effective and safe alternative therapy with zero reported serious adverse events from patients that have had this treatment. the providers that are conducting this study hypothesize that delivering microbes from a healthy human gut can help treat the damages caused by uc. this is done by "transplanting" fecal material, which contains a highly complex and dense community of healthy microbes, including bacteria, fungi and viruses. this collection of microbes is referred to as a microbiome. preliminary studies suggest that alteration of the microbiome can help treat uc.


Eligibility criteria:
inclusion criteria: * men or women 18-75 years of age. * established diagnosis of ulcerative colitis (uc) with known involvement of the left colon * mild to moderate disease defined as endoscopic evidence of disease with mayo endoscopic sub-score 1 or 2 and total mayo score ranging from 4-10. (the mayo score ranges from 0 to 12, with higher scores indicating more severe disease. this score can be used for both initial evaluation and monitoring treatment response). * patients may be on any class of ibd-related medication (excluding steroids) * patients must be on stable medication regimen for at least 6 weeks prior to enrollment. * ability to understand and willingness to sign informed consent document exclusion criteria: * patient who are asymptomatic * patients with severe, refractory disease (defined as mayo scores of \> 10, or endoscopic disease activity score of \> 3) or patients with any other significant condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety, tolerability of the investigational treatment or prevent compliance with the study protocol * prior colectomy * positive stool test for any of the following: clostridium difficile by pcr, salmonella, shigella, yersinia, campylobacter, enteropathogenic e. coli by standard stool culture. * use of the steroid medications (any formulation) in the prior 6 weeks to enrollment * systemic antibiotic use within prior 6 weeks to enrollment * regular probiotic supplement use within prior 48 hours to enrollment * pregnancy or breastfeeding * severe immunodeficiency, inherited or acquired (e.g. hiv, chemotherapy, or radiation therapy) * history of anaphylaxis (severe allergic reaction) * documented allergy to fluoroquinolones, metronidazole * life expectancy less than 12 months * age less than 18 or greater than 75 years of age * history of esophageal or gastric motility disorders.
identification of the mechanism of non-histaminergic itch inducing epigenetic changes

Conditions: Itch

Summary: itch is defined as an unpleasant sensation that evokes the desire to scratch. chronic itch, defined as itch persisting for more that 6 weeks, is a key symptom in many diseases severely affects the quality of life of the affected patients and represents a substantial economic burden for the society. at present, there are no effective treatments for chronic itch diseases. moreover, chronic itch patients express differences in their genes compared with people who do not suffer from itch. with this experiment, we wish to analyse differences in genes expression in healthy volunteers who have been exposed to artificial itch from small plant needles from the plant cowhage (mucuna pruriens) and compare them to controls who have not been exposed to itch.

the study takes place over 2 sessions over a period of 2 days. thirty healthy participants will be randomly allocated into two groups named "active group", treated with active cowhage spicules, and "control group", exposed to inactivated cowhage spicules. during the 1st session, the participant will fill out a questionnaire including basic information and after participants in the active group will be treated with cowhage spicules for 15 minutes, while participants in the control group will receive the inactivated cowhage spicules. all subjects will be provided with a visual analog scale in which they have to report continuously the sensation of itch and pain on a scale from 0 to 100 for 15 minutes. before cowhage application, 30 minutes and 3 hours after cowhage application, blood samples will be collected from all participants. the 2nd session will take place 24 h after the 1st session and in this session the final blood sample will be collected.

Eligibility criteria:
inclusion criteria: * healthy men and women * 18-60 years * speak and understand english exclusion criteria: * pregnancy or lactation * drug addiction defined as any use of cannabis, opioids, or other addictive drugs * previous or current history of neurological (e.g., neuropathy), immunological (e.g., asthma, immune deficiencies, arthritis) musculoskeletal (e.g., muscular pain in the upper extremities), cardiac disorder, or mental illnesses that may affect the results, * lack of ability to cooperate * current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids * allergy to lidocaine * skin diseases (e.g., atopic dermatitis, pruritus nodularis, eczema, psoriasis) * moles, scars, or tattoos in the area to be treated or tested. * consumption of alcohol or painkillers 24 hours before the study days and between these * smoking * acute or chronic pain * participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
safety and efficacy of as-3201 in the treatment of diabetic sensorimotor polyneuropathy

Conditions: Diabetic Neuropathy

Summary: this is a safety and efficacy trial of ranirestat(as-3201) which is an aldose reductase inhibitor in patients with diabetic sensorimotor polyneuropathy.


Eligibility criteria:
inclusion criteria: * patients with the following may enter: clinical signs and symptoms (footpain, numbness, tingling, weakness, etc.) of symmetrical distal diabetic sensorimotor polyneuropathy with diagnosis by nerve conduction tests and/or quantitative sensory test. * 18 to 70 years old of either sex and any race * type i or type ii, insulin-dependent or non insulin-dependent diabetes for at least six months prior to study entry * healthy in general * no hospitalizations for diabetic control or episodes of ketoacidosis for three months prior to screening * female patients of childbearing potential must have a negative serum pregnancy test exclusion criteria: * known non-diabetic causes of neuropathic symptoms * diabetic patients with no neuropathy or severe neuropathy * used any aldose reductase inhibitors within one year of screening * clinically significant illness including unstable cardiac, pulmonary, hematologic, hepatic, renal, or neoplastic disease * a history of systemic carcinoma within five years of screening * a history of epilepsy or serious head injury * a history or evidence of drug or alcohol abuse * test positive at screening for hepatitis b surface antigen or hepatitis c antibody or have a history of a positive result, or patients with evidence of significant hepatic insufficiency * a history of known or suspected diagnosis of aids, or have tested seropositive for hiv antibody or antigen previously

Keywords: diabetic sensorimotor polyneuropathy diabetic neuropathy
linear endosonography for the assessment of sarcoidosis stage o

Conditions: Lymphadenitis

Summary: patients are often referred for e(b)us examination and sampling of enlarged mediastinal and/or hilar lymph nodes that are not visible on a standard chest x-ray but are discovered by accident on ct scan performed outside the context of lung cancer or extrathoracic malignancies. since ct scan is largely used and e(b)us is a minimally invasive technique, these cases are explored more frequently but so far nothing is known, however, on the prevalence of abnormal findings in ebus sampling in this particular population and on the clinical implications (mainly therapeutical implications) of e(b)us findings.

the primary aim is to assess the nature and prevalence of abnormal findings in samplings obtained during e(b)us-na in the non-cancer patient with ct enlarged mediastinal/hilar lymph nodes that are not visible on chest x-ray. as secondary aims, the clinical implications of e(b)us-na findings will be assessed, in particular the number of cases where a specific treatment is initiated.

Eligibility criteria:
inclusion criteria: * patient referred to bronchoscopy for tissue diagnosis of discrete enlarged (≥10mm short axis diameter) mediastinal/hilar lymph nodes on ct scan that can be sampled by e(b)us-na. exclusion criteria: * abnormal chest x-ray showing hilar/mediastinal lymph nodes * patients with suspected lung cancer * patients with previous malignancy diagnosed and definitely treated less than 5 years previously or, if treated more than five years before but with subsequent evidence of recurrence less than 5 years previously. * patient with concomitant (suspected or confirmed) bronchopulmonary infection or treated with antibiotics within the 4 previous weeks * patients with a contraindication for bronchoscopy and tissue sampling

Keywords: endosonography enlarged thoracic lymph adenopathies non-cancer patient
multimodal analgesia effect on post surgical patient

Conditions: Obesity, Morbid; Surgery; Bariatric Surgery Candidate

Summary: patients undergoing bariatric surgery at the university of california davis medical center will be divided into two groups, one receiving standard of care pain control medications vs the second group which will receive non-narcotic pain medications with rescue pain medications available if needed

pain control after weight loss surgery is challenging due to the alteration of digestive system anatomy and limitation on using medications which can either be crushed or in liquid form for the first 10 days to 14 days after surgery. additionally there are multiple programs in place to eliminate the use of narcotic/opioid based pain medications due their potential addictive risks. this study compares two groups of patients whom will have roux en y gastric bypass surgery at uc davis medical center, the control group will receive standard of care pain control medications (including opioid based medications) compared to the research arm, this group will receive gabapentinin and tylenol for pain control after surgery with rescue pain medications available if needed. post surgery both groups will be managed by the bariatric surgery team and will be contacted periodically as part of the standard of care to monitor pain control and usage of any rescue medications (if needed).

Eligibility criteria:
inclusion criteria: * women who undergo index weight loss procedures at uc davis medical center * women with a bmi =\>30 * age from 35-65 * american society of anesthesiology (asa) score of 3 or less * no previous history of prior abdominal/foregut surgery exclusion criteria: * not having an index weight los surgery for obesity * do not meet the nih standards for weight loss surgery * additional planned or unplanned procedures during the index surgical procedure such as cholecystectomy or extensive lysis of adhesions (\>30 minutes) * bmi \< 30 * men * women considering or currently planning on gender altering/modification * asa score of 4 or higher * patients less than 35 years of age or older than 65 years of age at the time of surgical consent * a history of open abdominal surgery including umbilical, ventral, or splengalic hernia repair with or without mesh implantation, transplant or vascular surgery or any foregut procedures including hiatal hernia repair or anti-reflux surgery * arthritis, fibromyalgia, chronic pain syndrome * other conditions requiring daily use of oral pain medications * prisoners * allergy to gabapentin

Keywords: bariatric surgery, pain control gabapentinin
effects of neutrophil extracellular traps and damage-associated molecular pattern molecules on long term use of macrolides in adults with chronic respiratory disease

Conditions: Chronic Respiratory Disease

Summary: the purpose of this study is to investigate the effects of neutrophil extracellular traps and damage-associated molecular pattern molecules on long term use of macrolides in adults with chronic respiratory disease.

this study is a prospective, observational, non-interventional cohort study to explore investigate the effects of neutrophil extracellular traps and damage-associated molecular pattern molecules on long term use of macrolides in adults with chronic respiratory disease.the study subjects were adult patients with chronic respiratory disease who met the inclusion criteria in the outpatient department from august 2021 to august 2023. a face-to-face questionnaire survey was conducted. act score was used for asthma control evaluation. baseline data such as pulmonary function, feno, blood routine, induced sputum cell count, etc. were obtained. the use of hormones and other drugs was recorded. inflammatory biomarkers were detected. 20ml venous blood was drawn to extract neutrophils to detect the expression of neutrophil extracellular traps and rt-pcr and elisa were used to detect the expression of damps. the total study duration was 2 years, with telephone visits every 3 months to assess chronic respiratory disease control and record subject compliance, unscheduled outpatient, emergency, and inpatient status.

Eligibility criteria:
inclusion criteria: * 1）age ≥ 18 years; 2）gender: not limited; 3）diagnosis of asthma according to gina guidelines (version 2021). 4）copd was diagnosed according to gold guidelines (version 2021). 5）acos was diagnosed according to the consensus criteria for asthma-chronic obstructive pulmonary overlap syndrome (version 2021). exclusion criteria: * 1) acute heart failure, severe organ failure, malignant tumors; 2) other lung diseases such as pulmonary infection，pulmonary hypertension,tumor which seriously affect lung function, sputum cell classifi cation and other test results; 3) pregnancy and lactation; 4) recent surgery history.

Keywords: neutrophil extracellular traps damage-associated molecular pattern molecules macrolides
expanding donor pool for live donor liver transplantation: utilization of donors with nash after optimization

Conditions: Non Alcoholic Steatohepatitis

Summary: live donor liver transplantation (ldlt) is the treatment of choice for end-stage liver disease, predominantly in the east, where deceased donor liver transplantation is sparse. in ldlt, donor selection has to be stringent; as the donor safety is thepriority. live liver donors (lld) with complex biliary and vascular anatomy are increasingly being accepted for donation with the betterment of technical expertise. one of the commonest reasons for lld rejection is the hepatic parenchymal abnormality because ofsteatosis and steatohepatitis, which can increase the donor risk. retrospective analysis of donors with non-alcoholic steatohepatitis(nash) who were optimized and taken up for major hepatectomy from june 2011 to january 2018will be performed.

study design aim and objective - * primary objective: * to study the effect of donor optimization protocol in donors with biopsy proven nash * to study thebiochemical (lftss \& inr) recovery in donors with nash after major hepatectomy * to compare their biochemical recovery parameters (lfts \& inr) with that of non nash donors. * secondary objectives: * to study incidence of nash among live liver donors * to study their respective recipients' outcomes * to study the morbidity among llds with nash after major hepatectomy methodology: * study population:patients underwentldlt from june 2011 to january 2019 at institute of liver \& biliary sciences, new delhi * study design:retrospective study * study period:from june 2011 to january 2019 * sample size with justification:all consecutive llds with at least one year of follow up post-operatively * intervention: none * monitoring and assessment:none statistical analysis:categorical variables were presented as number (percentage) and were compared using the chi-square test. continuous variables were presented as mean (standard deviation, sd) and were compared using mann-whitney u test. adverse effects: none stopping rule of study: none expected outcome of the project: adherence to a strict dietary and lifestyle modifications plan will cause histological reversal of nash and fibrosis in llds. their clinical and biochemical recovery following the major hepatectomy will be similar to that of non-nash llds.

Eligibility criteria:
inclusion criteria: 1. live liver donors who had undergone major hepatectomy (removal of ≥ 3 liver segments) exclusion criteria: 1. live liver donors who had undergone minor hepatectomy (removal of \< 3 liver segments) 2. live liver donors of recipients with acute liver failure.
kinesiotaping along with mulligan's mobilization with movement in adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the study aimed to evaluate the effectiveness of combining kinesiotaping with mulligan's mobilization with movement in treating shoulder adhesive capsulitis. thirty patients participated in a randomized control trial, divided equally into an experimental group and a control group. the experimental group received kinesiotaping, mulligan's mobilization with movement, and conventional physiotherapy, while the control group received only mulligan's mobilization with movement and conventional physiotherapy. pain, range of motion, and functional outcomes were measured using a visual analogue scale, goniometer, and the shoulder pain and disability index (spadi) questionnaire.


Eligibility criteria:
inclusion criteria: * primary adhesive capsulitis, * controlled diabetes mellitus, * restriction of movements in capsular pattern, * shoulder pain for more than one month. exclusion criteria: * secondary adhesive capsulitis, * cancer, * bilateral adhesive capsulitis, * skin infections in the shoulder region, * shoulder joint infections, * wounds or ulcers in the shoulder region, * hypersensitivity to tape, * recent shoulder dislocation, * recent shoulder fractures.

Keywords: rehabilitation manual therapy exercise therapy shoulder pain
a single-dose study to investigate the effects of 4 different doses of inhaled azd8683 in chronic obstructive pulmonary disease (copd) patients

Conditions: Chronic Obstructive Pulmonary Disease; COPD

Summary: this study in chronic obstructive pulmonary disease (copd) patients will investigate the bronchodilatory effect of azd8683. azd8683 will be tested versus placebo and an active comparator.

a randomised, double-blind placebo- and active-controlled, multi-centre, 6-way cross-over, single-dose phase iia study to investigate the bronchodilatory and systemic effects of 4 different doses of inhaled azd8683 in patients with chronic obstructive pulmonary disease (copd).

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures male or female, age ≥ 40 years at visit 1. women must be of non-childbearing potential or must have been stable on a highly effective contraceptive method for at least 3 months prior to visit 1 and be willing to continue until follow-up * clinical diagnosis of copd for more than 1 year at visit 1 * fev1 ≥ 30 to \< 80% of the predicted normal value (post-bronchodilator) at visit 2 and post-bronchodilator fev1/fvc \< 70% * reversible airway obstruction exclusion criteria: * significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result of the study, or the patient's ability to participate in the study. * an exacerbation of copd (defined as use of oral/parenteral glucocorticosteroids (gcs) and/or antibiotics and/or hospitalisation related to copd) within 6 weeks of visit 1or during the enrolment period * treatment with systemic gcs within 6 weeks of visit 2 or during the enrolment period * respiratory tract infection of clinical relevance within 30 days of visit 4, as judged by the investigator * long-term oxygen therapy, as judged by the investigator

Keywords: copd chronic obstructive pulmonary disease